• Sponsored Content

BPI Staff

July 22, 2019

1 Min Read

2019-BIO-Theater-Pfenex-Exec-Interview-300x155.pngOn Wednesday, 5 June 2019, Patrick Lucy, chief business officer at Pfenex, told a crowded BPI Theater at BIO about the evolution of his company. While the firm approaches approval of PF708, a therapeutic equivalent to Eli Lilly’s Forteo treatment, Pfenex’s future will focus on novel therapies and strategic partnerships revolving around next-generation antibodies and its gene expression technology.

You May Also Like